Mesoblast (NASDAQ:MESO) Stock Price Breaks Below 50 Day Moving Average - Should You Sell?

Key Points

• Mesoblast shares fell below their 50-day moving average, trading as low as $14.27 versus a 50-day average of $15.78. The stock is down 0.1%, while its 200-day moving average stands at $15.27.
• Analyst sentiment is mixed: Piper Sandler and Cantor Fitzgerald maintained “overweight” ratings, while Weiss Ratings upgraded the stock’s rating from “sell (e+)” to “sell (d-).” Overall, analysts rate Mesoblast “Hold,” with an average price target of $39.00.
• Mesoblast reported a quarterly loss of $0.07 per share on $34.45 million in revenue, and analysts expect a full-year loss of $0.05 per share. Institutional ownership remains limited at 1.43%, although several investors—including Bank of America—recently increased their stakes.

Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $15.78 and traded as low as $14.27. Mesoblast shares last traded at $14.27, with a volume of 143,761 shares traded.

Wall Street Analyst Weigh In

Several analysts recently weighed in on MESO shares. Piper Sandler reissued an "overweight" rating and issued a $39.00 price objective (up from $35.00) on shares of Mesoblast in a report on Thursday, August 27th. Weiss Ratings upgraded Mesoblast from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Mesoblast in a report on Thursday, September 24th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Mesoblast presently has an average rating of "Hold" and an average target price of $39.00.

Mesoblast Stock Down 0.1%

The company's fifty day moving average price is $15.78 and its 200 day moving average price is $15.27. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.43 and a quick ratio of 2.09.

Mesoblast (NASDAQ:MESO - Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported ($0.07) earnings per share for the quarter. The company had revenue of $34.45 million for the quarter. Equities analysts forecast that Mesoblast Limited will post -0.05 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in MESO. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Mesoblast in the 4th quarter worth about $32,000. GAMMA Investing LLC lifted its position in Mesoblast by 14.1% in the 2nd quarter. GAMMA Investing LLC now owns 7,413 shares of the company's stock valued at $100,000 after purchasing an additional 916 shares during the last quarter. Tobias Financial Advisors Inc. boosted its stake in Mesoblast by 38.3% during the 4th quarter. Tobias Financial Advisors Inc. now owns 13,828 shares of the company's stock valued at $249,000 after purchasing an additional 3,828 shares during the period. Royal Bank of Canada boosted its stake in Mesoblast by 22.5% during the 1st quarter. Royal Bank of Canada now owns 26,266 shares of the company's stock valued at $404,000 after purchasing an additional 4,827 shares during the period. Finally, Bank of America Corp DE grew its position in Mesoblast by 608.4% in the 1st quarter. Bank of America Corp DE now owns 100,004 shares of the company's stock worth $1,538,000 after purchasing an additional 85,888 shares during the last quarter. 1.43% of the stock is currently owned by institutional investors.

About Mesoblast

Mesoblast Limited is a regenerative medicine company that develops and commercializes cellular medicines for serious inflammatory and immune-mediated conditions. The company's platform is based primarily on specialized allogeneic mesenchymal lineage precursor cells, which are obtained from healthy adult donors and developed for use without patient-specific matching.

Mesoblast's lead commercial product, Ryoncil (remestemcel-L), is an off-the-shelf cell therapy approved in the United States for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.